Cadence plans to try again for FDA approval of Ofirmev

04/19/2010 | Bloomberg Businessweek

Cadence Pharmaceuticals plans to resubmit its pain and fever medicine Ofirmev for FDA approval within the next 30 days. In a meeting with the agency and a third-party manufacturer, the drugmaker said the agency did not request additional data on the drug, an injectable version of acetaminophen that was rejected by the FDA in February because of manufacturing concerns.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
Boise, ID